REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 227.00
Bid: 220.00
Ask: 234.00
Change: 12.00 (5.58%)
Spread: 14.00 (6.364%)
Open: 215.00
High: 235.00
Low: 215.00
Prev. Close: 215.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Retailers Hit As John Lewis Profit Collapses

Thu, 13th Sep 2018 10:49

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Royal Bank of Scotland, up 1.5%. The state-backed lender could use up to GBP4 billion of extra capital to pay out a special dividends to shareholders, The Times newspaper reported. RBS Chairman Howard Davies told the newspaper that, despite wanting to use the spare cash to buy the bank's shares from the government, if shareholders wanted the special dividend it was a possible option. The special dividend could be up to 33 pence per share to investors, who have not received a payout from the bank in more than 10 years, the newspaper reported. "If there are a lot of shareholders pressing for a special dividend, that is something we would consider," Davies told the Times. ----------Antofagasta, up 0.9%. HSBC raised the Chilean copper miner to Hold from Reduce. ----------FTSE 100 - LOSERS----------Marks & Spencer Group, down 2.7%. Shares in the food, clothing and homewares retailer were lower after department store chain John Lewis Partnership issued a warning for the full-year, amid "challenging times in retail". For the six months to July 28, John Lewis Partnership, which also owns the Waitrose supermarket chain, reported 81% drop in pretax profit to GBP6.0 million from GBP30.8 million a year before. On an adjusted basis, pretax profit slumped 99% to GBP1.2 million. At the end of June, the company had said it expected its interim profit to be "near zero". Looking ahead, John Lewis said that it continues to expect full-year profits to "be substantially lower than last year for the group as a whole". "John Lewis is the bellwether of the UK retail sector, so the fact it's finding life so hard is an indication of just how dire things are on the high street right now," said Hargreaves Lansdown analyst Laith Khalaf. Rival chain Debenhams was down 11%. ----------FTSE 250 - WINNERS----------Grainger, up 5.3%. The residential landlord was raised to Buy from Add by Numis. ----------KAZ Minerals, up 1.8%. HSBC upgraded the Kazakhstan-based miner to Buy from Hold. ----------FTSE 250 - LOSERS----------Inmarsat, down 2.0%, Equiniti Group, down 1.8%. The stocks went ex-dividend meaning new buyers no longer qualify for the latest dividend payout. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Bushveld Minerals, up 18%. The miner said it has raised its interest in the Vametco vanadium mine located near Pretoria, South Africa, to 75% from 59.1%. Bushveld has acquired the entire 21.22% interest that Sojitz Noble Alloys Corp held in Strategic Minerals Corp, the 75% owner of Vametco, for USD20 million in cash. Following completion of the deal, Bushveld via its Bushveld Vametco unit will own 100% of Strategic Minerals Corp and therefore have an indirect beneficial interest of 75% in the Vametco mine. The company used its existing cash resources to complete the stake acquisition.----------OTHER MAIN MARKET AND AIM - LOSERS----------Faron Pharmaceuticals, down 15%. The biopharmaceutical company said its loss for the first half of its financial year increased on higher research costs. For the six months to June 30, the firm posted pretax loss of EUR14.1 million compared to EUR7.1 million a year prior on increased research & development costs by 95% year-on-year to EUR11.7 million from EUR6.0 million. Administrative expenses also increased to EUR2.4 million from EUR1.5 million. As the company focuses on developing drugs, it only generated revenue of EUR20,000 from product sales to Maruishi Pharmaceutical. A year ago revenue was nil. Research expenses increased as a result of clinical costs associated with an unsuccessful trial of Traumakine, a treatment for acute respiratory distress syndrome, as well as an increase in development activities for Clevegen, a potential treatment for various types of cancer, the company explained.----------
More News
3 May 2024 13:39

TRADING UPDATES: Kelso raises stake in NCC; Transense joins project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News:

Read more
30 Apr 2024 16:33

Faron Pharmaceuticals extends funding agreement with IPF

(Sharecast News) - Faron Pharmaceuticals announced on Tuesday that it has extended its agreement with lender IPF to ensure continued financial support as it progressed towards securing longer-term funding.

Read more
15 Apr 2024 10:58

Faron Pharmaceuticals reappoints former finance chief on interim basis

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it appointed a new interim chief financial officer to replace the outgoing James O'Brien.

Read more
15 Apr 2024 09:36

Faron Pharmaceuticals CFO stands down

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals revealed on Monday that chief financial officer James O'Brien would be leaving the group to "pursue another career opportunity".

Read more
8 Apr 2024 11:50

UPDATE: Faron Pharmaceuticals promotes COO to CEO as father retires

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace his father, the company's founder.

Read more
8 Apr 2024 11:28

Faron Pharmaceuticals promotes COO to CEO as founder steps back

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it will promote its chief operating officer to chief executive to replace the company's founder.

Read more
8 Apr 2024 09:17

Faron Pharmaceuticals taps Juho Jalkanen for CEO

(Sharecast News) - Biopharmaceutical company Faron Pharmaceuticals named Dr Juho Jalkanen as its next chief executive officer on Monday.

Read more
4 Apr 2024 11:58

Faron Pharmaceuticals secures funding to deliver next "milestones"

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it has successfully raised funds to support the phase two study of its bexmarilimab cancer treatment.

Read more
3 Apr 2024 10:59

TRADING UPDATES: Quiz sales fall, names new CEO; Byotrol eyes AIM exit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
2 Apr 2024 13:22

UK shareholder meetings calendar - next 7 days

Wednesday 3 April 
Downing Strategic Micro-Cap Investment Trust PLCGM re approval of B share scheme
Quantum Exponential Group PLCGM re delisting or potential investment in company
Thursday 4 April 
Rio Tinto PLCAGM
Scottish American Investment Co PLCAGM
TheWorks.co.uk PLCGM re Main Market delisting and AIM admission
Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 17:09

LONDON MARKET CLOSE: Stocks downbeat before central bank rate storm

(Alliance News) - Stocks in London closed in the red on Monday, as tech gains in New York failed to make an impact ahead of several interest rate decisions from central banks across the world this week.

Read more
18 Mar 2024 14:14

Faron shares jump on encouraging trial data

(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-risk (HR) myelodysplastic syndrome (MDS) patients who had failed prior hypomethylating agent (HMA) treatment.

Read more
18 Mar 2024 11:41

Faron Pharmaceuticals shares jump on positive data from Bexmab study

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said a study showed more patients responding to treatment in a new readout of the Bexmab study focused on myelodysplastic syndrome, or MDS.

Read more
18 Mar 2024 10:05

AIM WINNERS & LOSERS: Clontarf raises GBP400,000; Faron jumps

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
13 Mar 2024 20:49

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.